Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF

被引:9
|
作者
Romiti, Giulio Francesco [1 ,2 ,3 ]
Proietti, Marco [4 ,5 ]
Corica, Bernadette [1 ,2 ,3 ]
Bonini, Niccolo [1 ,2 ,6 ]
Boriani, Giuseppe [6 ]
Huisman, Menno V. [7 ]
Lip, Gregory Y. H. [1 ,2 ,8 ]
机构
[1] Liverpool John Moores Univ, Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[5] IRCCS Ist Clin Sci Maugeri, Div Subacute Care, Milan, Italy
[6] Univ Modena & Reggio Emilia, Policlin Modena, Div Cardiol, Dept Biomed Metab & Neural Sci, Modena, Italy
[7] Leiden Univ, Dept Thrombosis & Hemostasis, Med Ctr, Leiden, Netherlands
[8] Aalborg Univ, Danish Ctr Clin Hlth Serv Res, Dept Clin Med, Aalborg, Denmark
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2023年 / 12卷 / 20期
关键词
anticoagulation; atrial fibrillation; clinical complexity; elderly individuals; outcomes; EUROBSERVATIONAL RESEARCH-PROGRAM; ANTICOAGULATION; STROKE; IMPACT; BARRIERS; OUTCOMES; PATHWAY; CARE;
D O I
10.1161/JAHA.123.030565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical risk factors are common among patients with atrial fibrillation (AF), but there are still limited data on their association with oral anticoagulant (OAC) treatment patterns and major outcomes. We aim to analyze the association between clinical risk phenotypes on AF treatment patterns and the risk of major outcomes. METHODS AND RESULTS: The GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation) phase 2 and 3 registries enrolled patients with a recent diagnosis of AF between 2011 and 2016. We defined 4 features of clinical risk among patients with CHA(2)DS(2)-VASc >= 2: elderly individuals (aged >= 80 years), chronic kidney disease (estimated glomerular filtration rate <45 mL/min), history of stroke, and history of bleeding. We analyzed the odds of receiving OAC and the risk of OAC discontinuation and adverse events at follow-up according to specific combinations and cumulative burden of these features. Primary outcome was the composite of all-cause death, thromboembolism, and major bleeding. Among 28 891 (mean +/- SD age, 70.1 +/- 10.5 years; 45.5% women) patients included, 10 797 (37.3%) had at least 1 clinical risk feature. OAC use was lower among patients in the elderly group (odds ratio [OR], 0.85 [95% CI, 0.75-0.96]), those with history of both stroke and bleeding (OR, 0.45 [95% CI, 0.35-0.56]), and those with multiple features (OR, 0.71 [95% CI, 0.62-0.82]). Increasing burden of clinical risk features was associated with OAC discontinuation, with highest magnitude in those with >= 3 features (hazard ratio [HR], 1.68 [95% CI, 1.31-2.15]). Groups with increasingly complex clinical risk phenotypes were associated with the occurrence of the primary composite outcome, with the highest figures observed for groups with a history of both stroke and bleeding (adjusted HR, 2.36 [95% CI, 1.83-3.04]) and multiple features (adjusted HR, 2.86 [95% CI, 2.52-3.25]). CONCLUSIONS: In patients with AF, clinical risk phenotypes are multifaceted and heterogenous, and they are associated with differences in stroke prevention and worse prognosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] History of major bleeding predicts risk of clinical outcome of patients with atrial fibrillation: results from the COOL-AF registry
    Krittayaphong, Rungroj
    Winijkul, Arjbordin
    Wongtheptien, Wattana
    Wongvipaporn, Chaiyasith
    Wisaratapong, Treechada
    Kunjara-Na-Ayudhya, Rapeephon
    Boonyaratvej, Smonporn
    Kaewcomdee, Pontawee
    Yindeengam, Ahthit
    JOURNAL OF GERIATRIC CARDIOLOGY, 2020, 17 (04) : 184 - 192
  • [42] Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening
    Gibbs, Harry
    Freedman, Ben
    Rosenqvist, Marten
    Virdone, Saverio
    Al Mahmeed, Wael
    Ambrosio, Giuseppe
    Camm, A. John
    Jacobson, Barry
    Jerjes-Sanchez, Carlos
    Kayani, Gloria
    Oto, Ali
    Panchenko, Elizaveta
    Ragy, Hany
    Kakkar, Ajay K.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (07) : 893 - +
  • [43] Clinical phenotype classification to predict risk and optimize the management of patients with atrial fibrillation using the Atrial Fibrillation Better Care (ABC) pathway: a report from the COOL-AF registry
    Krittayaphong, R.
    Treewaree, S.
    Wongtheptien, W.
    Kaewkumdee, P.
    Lip, G. Y. H.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2023, : 16 - 23
  • [44] Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial
    Wilkinson, Chris
    Wu, Jianhua
    Searle, Samuel D.
    Todd, Oliver
    Hall, Marlous
    Kunadian, Vijay
    Clegg, Andrew
    Rockwood, Kenneth
    Gale, Chris P.
    BMC MEDICINE, 2020, 18 (01)
  • [45] Risk factor management of atrial fibrillation using mHealth: The Atrial Fibrillation - Helping Address Care with Remote Technology (AF-HEART) Pilot Study
    Mitrani, Lindsey R.
    Goldenthal, Isaac
    Leskowitz, Jamie
    Wan, Elaine Y.
    Dizon, Jose
    Saluja, Deepak
    Creber, Ruth Masterson
    Turchioe, Megan Reading
    Sciacca, Robert R.
    Garan, Hasan
    Hickey, Kathleen T.
    Korner, Judith
    Biviano, Angelo B.
    CARDIOVASCULAR DIGITAL HEALTH JOURNAL, 2022, 3 (01): : 14 - 20
  • [46] Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF
    Barnett, Adam S.
    Cyr, Derek D.
    Goodman, Shaun G.
    Levitan, Bennett S.
    Yuan, Zhong
    Hankey, Graeme J.
    Singer, Daniel E.
    Becker, Richard C.
    Breithardt, Guenter
    Berkowitz, Scott D.
    Halperin, Jonathan L.
    Hacke, Werner
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Fox, Keith A. A.
    Patel, Manesh R.
    Piccini, Jonathan P.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 257 : 78 - 83
  • [47] Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registryTrends in antithrombotic therapy use in China
    Xiaoxia Liu
    Guoze Feng
    Sabrina Vogel Marler
    Menno V Huisman
    Gregory Y. H. Lip
    Changsheng Ma
    Thrombosis Journal, 21
  • [48] Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF
    Johnson, Linda S.
    Benz, Alexander P.
    Shoamanesh, Ashkan
    Eikelboom, John W.
    Ezekowitz, Michael
    Giugliano, Robert P.
    Wallentin, Lars
    Ruff, Christian T.
    Lopes, Renato D.
    Jolly, Sanjit
    Whitlock, Richard
    Granger, Christopher B.
    Connolly, Stuart
    Healey, Jeffrey S.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (17):
  • [49] The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report
    Hammer, Andreas
    Schnaubelt, Sebastian
    Niessner, Alexander
    Sulzgruber, Patrick
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2020, 4 (05)
  • [50] Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
    Ding, Wern Yew
    Fawzy, Ameenathul Mazaya
    Romiti, Giulio Francesco
    Proietti, Marco
    Pastori, Daniele
    Huisman, Menno V.
    Lip, Gregory Y. H.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (01) : 39 - 49